Interpace Biosciences is a molecular diagnostics company focused on thyroid cancer testing. The core problem Interpace addresses is that roughly 25% of thyroid biopsies — over 100,000 per year in the U.S. — return inconclusive results from standard cytopathology, historically leading physicians to recommend surgery. Studies show about 77% of those surgically removed nodules are benign, so Interpace's tests help physicians avoid unnecessary surgeries by better characterizing malignancy risk upfront. Interpace's two commercial products work as a combined platform: ThyGeNEXT, a DNA and RNA sequencing panel that identifies oncogenic mutations associated with thyroid cancer, and ThyraMIR v2, a microRNA classifier that refines malignancy risk and is reflexed after ThyGeNEXT about 85% of the time. Interpace performs testing in its CLIA-certified lab in Pittsburgh, billing payers per test. Revenue depends on test volume, reimbursement coverage, and reimbursement rates. Interpace is currently out-of-network with most commercial insurers, creating billing uncertainty; securing in-network contracts is a key priority. Interpace's largest customer is LabCorp, which aggregates and routes specimens to the Pittsburgh lab. The company recently discontinued its PancraGEN pancreatic cyst test after CMS withdrew reimbursement coverage, and is now entirely focused on thyroid diagnostics. Growth priorities include expanding the sales force, securing commercial payer contracts, and exploring partnerships or acquisitions to add new tests. Ownership is highly concentrated, with private equity firms Ampersand and 1315 Capital collectively controlling roughly 84% of outstanding common stock.